---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-017753"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T21:00:20.263455+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Voyager Q3 net loss $25.9M; advances VY-TAU01 IND, SOD1 ALS candidate selection by year-end

## Summary
- Net loss $25.9M in Q3 2023 vs net income $17.6M in Q3 2022; collaboration revenue fell to $4.6M from $41.1M.
- Cash, equivalents and marketable securities $252.9M as of Sep 30, 2023; runway expected into mid-2025.
- Initiated GLP tox for anti-tau antibody VY-TAU01; IND filing expected H1 2024 for Alzheimer's disease.
- SOD1 ALS gene therapy program on track for development candidate selection in 2023, IND target mid-2025.
- License of TRACER capsid from Pfizer to Alexion/AstraZeneca Rare Disease assigned; terms unchanged.

## SEC filing metadata
- accession: 0001558370-23-017753
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000155837023017753/0001558370-23-017753-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000155837023017753/vygr-20231106x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-017753
- JSON: https://secwatch.observer/filing/0001558370-23-017753.json
- Plain text: https://secwatch.observer/filing/0001558370-23-017753.txt

## Key facts
- Earnings Releases
  Voyager Therapeutics, Inc. updated its mid-2025 guidance (reaffirmed).
  - Period: mid-2025
  - Guidance: reaffirmed
  - Result: guidance update
  source text: We expect our cash, cash equivalents, and marketable securities, along with amounts expected to be received as reimbursement for development costs under the Neurocrine collaborations and interest income, to be sufficient to meet Voyager’s planned operating expenses and capital expenditure requirements into mid-2025 .
  evidence_url: https://www.sec.gov/Archives/edgar/data/1640266/000155837023017753/0001558370-23-017753-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.